Inability or unwillingness to swallow pills
Inability to comply with protocol-required procedures
Inability or unwillingness to swallow pills
Inability to cooperate with treatment protocol
Inability to comply with study and/or follow-up procedures.
Inability to comply with study-related procedures
Inability to comply with protocol-mandated hospitalization and activities restrictions
Inability to comply with requirements for cisplatin administration anti-emetic regimens post-treatment
Inability or unwillingness to swallow pills
Unwillingness or inability to comply with procedures required in this protocol
Inability to comply with study and follow up procedure
Inability to comply with study and follow up procedure
Inability to receive HCT due to alloimmunization, defined as the inability to receive packed red blood cell (pRBC) transfusion therapy.
Inability to cooperate with treatment protocol
Inability to comply with study requirements
Inability to complete baseline QOL forms
Inability to swallow medications
Inability to comply with study and follow-up procedures.
Inability to comply with study and/or follow-up procedures
Inability to swallow pills
Inability to swallow pills
Inability to swallow pills
Inability to swallow pills
Inability or unwillingness to swallow whole pills
Inability to swallow pills;
Patient with inability to follow up.
Inability to tolerate CPI therapy {if already starte
The patient has an inability or unwillingness to abide by the study protocol or cooperate fully with the Investigator or designee.
Inability to swallow pills
Unwillingness or inability to comply with study procedures
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment.
Inability or unwillingness (including psychological, familial, sociological, or geographical conditions) to comply with study and/or follow-up procedures as outlined in the protocol.
Inability to swallow or absorb drug
Unwillingness to participate or inability to comply with the protocol for the duration of the study
Inability to comply with study and/or follow-up procedures
Inability to comply with study and/or follow-up procedures
Unwillingness or inability to comply with study and follow-up procedures
Inability to comply with protocol requirements
Inability to comply with study procedures
Inability or unwillingness to give informed consent
Inability to take ixazomib or abatacept
Central nervous system (CNS) diseases and major psychiatric diseases or inability to comply to the protocol procedures
Rapidly progressive disease which, in the opinion of the investigator, may predispose to inability to tolerate treatment or trial procedures
Inability to comply with the protocol and/or not willing or not available for followup assessments
Inability to comply with protocol required procedures
GENERAL: Inability to comply with study and follow-up procedures.
Unwillingness or inability to follow the procedures required in the protocol.
Inability to swallow medications
Inability to tolerate premedication with dexamethasone
Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.
Inability to swallow pills
Inability or unwillingness to swallow oral medications
Inability to adhere to study and/or follow-up procedures
Inability to comply with study and follow-up procedures.
Inability to comply with treatment per investigator discretion
Inability to follow standard of care follow up recommendations per investigator discretion
Inability to comply with study procedures or willingness to use adequate birth control
Inability to understand the informed consent document, to give consent voluntarily or to complete the study tasks, especially inability to understand and fulfill the health-related QOL questionnaire;
Inability to attend scheduled clinic visits
Inability to perform PFTs
Unwillingness or inability to follow the procedures required in the protocol.
Inability to comply with study and follow up procedures
Inability or unwillingness to swallow
Inability to comply with study and follow-up procedures
Inability to tolerate prophylactic anti-thrombotic therapy
Inability or unwillingness to swallow pills
Inability to comply with study and follow-up procedures
Inability to comply with protocol requirements
Inability to comply with treatment per investigator discretion
Inability to complete neurocognitive assessments per investigator discretion
Inability to comply with study and follow-up procedures
Unwillingness or inability to follow the procedures required in the protocol
Perceived inability to tolerate diagnostic or therapeutic procedures
Noncompliance - inability or unwillingness to comply with medical recommendations regarding therapy or follow-up, including smoking tobacco
Inability or unwillingness to swallow pills.
Inability to comply with the study and follow-up procedures.
Inability to comply with protocol requirements
Inability to comply with study and follow-up procedures
Inability to comply with study and follow-up procedures
Inability to tolerate thromboprophylaxis (Cohorts B, C, E, F)
Inability to comply with study and follow-up procedures
Unwillingness or inability to comply with procedures required in this protocol
Inability to comply with medical therapy or follow-up
Unwillingness or inability to comply with procedures required in this protocol
Inability to co-operate with the requirements of the protocol
Inability to comply with protocol or study procedures
Inability to tolerate anesthesia
Unwillingness or inability to comply with study and follow-up procedures
Inability to lie flat on a treatment table for > 60 minutes
Inability or unwilling to swallow study drug
Inability to comply with protocol requirements
Unwillingness or inability to comply with study and follow-up procedures
Inability to comply with study and/or follow-up procedures
Inability to give informed consent and comply with the protocol.
Inability to cooperate with the requirements of the protocol
Inability to comply with protocol required procedures
Inability to undergo contrast radiological assessments
Inability to take or tolerate enteral medications
Inability to comply with protocol requirements
Inability to comply with medical therapy or follow-up
Inability or unwillingness to comply with study procedures and protocol
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment
Inability to comply with protocol requirements
Inability to comply with study and/or follow-up procedures
Inability to swallow medications
Inability to comply with study procedures.
No unwillingness or inability to follow protocol requirements
Inability to consent
Unwillingness or inability to follow the procedures required in the protocol
Inability to comply with study and/or follow-up procedures
Inability to comply with protocol or study procedures
Inability to provide consent
Inability to comply with protocol requirements
Unwillingness or inability to comply with the study protocol for any other reason
Inability or unwillingness to comply with, or follow study procedures
Inability to adhere to study and/or follow-up procedures
Unwillingness or inability to comply with the study protocol for any other reason
Inability to comply with medical therapy or follow-up
Inability to comply with study and/or follow-up procedures
Inability or unwillingness to return for all the required follow-up visits
Inability to deliver target dose with CyberKnife due to inability to image fiducials
Inability or unwillingness to return for all the required follow-up visits
Inability to comply with protocol requirements, including pharmacokinetic (PK) studies (phase I only) and genetic studies
Unwillingness or inability to comply with the study protocol for any reason
Inability to lie flat for > 1 hour
COHORTS 1 AND 2: HEALTHY VOLUNTEERS: Inability to comply with the requirements of the protocol
Inability to comply with protocol requirements
Inability or unwillingness to comply with radiation safety procedures or protocol requirements
Inability to practice contraception with condoms as prescribed by the protocol
Inability to comply with study and/or follow-up procedures
Inability to comply with protocol requirements
Inability to co-operate with the requirements of the protocol
Inability or unwillingness to comply with radiation safety procedures or protocol requirements
Contraindication to SBRT (this includes the inability to cooperate with any aspect of SBRT: such as the inability to lie still and breathe reproducibly)
Unwillingness or inability to follow the procedures outlined in the protocol
Inability or unwillingness to sign the informed consent form.
Inability to continue taking ibrutinib for any reason
Inability to comply with study and follow-up procedures.
Inability or unwillingness to swallow pills.
Inability to comply with the study and follow-up procedures.
Inability to comply with the study and follow-up procedures
Inability to swallow intact tablets or inability to take pembrolizumab or cabozantinib
Inability or unwillingness to comply with study and/or follow-up requirements
Unwillingness to participate or inability to comply with the protocol for the duration of the study
Inability to give consent or adhere to follow-up schedule
An unwillingness or inability (including psychological, familial, sociological, or geographical conditions) to comply with trial and/or follow-up procedures as outlined in the protocol
Inability to comply with study and follow-up procedures as judged by the investigator
Inability to have fiducial markers placed
Inability or unwillingness to tolerate endocrine therapy
Inability or unwillingness to have pleural catheter placed
Inability to tolerate thromboprophylaxis
Inability to comply with study instructions
Inability to test core biopsy for study markers
Inability to comply with protocol
Inability to comply with study and/or follow-up procedures
Inability to home monitor blood pressure
Inability to comply with study and follow-up procedures
Inability to comply with study and/or follow-up procedures
Contraindication to SBRT or TEMLA; this includes the inability to cooperate with any aspect of SBRT such as the inability to lie still and breathe reproducibly
Subject has an inability or unwillingness, in the opinion of the investigator, to comply with the protocol requirements
Inability to take medications by mouth
Inability to inject medication or test for finger stick glucose
Inability to comply with study and/or follow-up procedures
High risk of inability to comply with transplant protocol, or inability to give appropriate informed consent in the estimation of the principal investigator (PI), social work, psychiatry, or the stem cell transplant team
Inability or unwillingness to return to required visits and follow-up exams
Inability to comply with the treatment protocol or to undergo pre-specified follow-up tests for safety or effectiveness
Inability to comply with the protocol and/or not willing or not available for follow-up assessments
Unwillingness to give written informed consent, unwillingness to participate, or inability to comply with the protocol for the duration of the study
Unwillingness or inability to comply with protocol.
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment.
Unwillingness or inability to comply with procedures required in this protocol.
Inability to comply with study and/or follow-up procedures
Inability to comply with other requirements of the protocol
Inability to comply with study and follow-up procedures
Inability to tolerate transrectal ultrasound (TRUS).
Inability to Participate Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.
Inability to swallow oral medication or inability or unwillingness to comply with the administration requirements related to alisertib
Inability to comply with protocol requirements
Inability to comply with study and follow-up procedures
Have a perceived inability to tolerate diagnostic or therapeutic procedures, particularly treatment in radiation isolation
Rapidly progressive disease which, in the opinion of the Investigator, may predispose to inability to tolerate treatment or trial procedures
Inability to tolerate thromboprophylaxis
Participants' inability to adhere to or tolerate protocol or study procedures.
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements or GI procedure that could interfere with the oral absorption or tolerance of treatment
Unwillingness or inability to comply with the protocol
Inability to comply with study and follow-up procedures
Unwillingness or inability to follow the procedures required in the protocol
Inability to tolerate PO dosing
Inability to comply with IL-2 treatment regimen
Participants with inability to comply with IL-2 treatment regimen
Inability or unwillingness to swallow pills
Inability to comply with the study and follow-up procedures
Inability to swallow oral medication or inability or unwillingness to comply with the administration requirements related to alisertib
Inability to comply with study and/or follow-up procedures
Inability to comply with the protocol and/or not willing or not available for follow-up assessments
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment.
Inability to co-operate with the requirements of the protocol
Inability to lie on the TomoTherapy treatment table for one hour
Unwillingness or inability to comply with study and follow-up procedures
Unwillingness to participate or inability to comply with the protocol for the duration of the study
Unwillingness or inability to provide written informed consent and comply with the study protocol for any reason
Inability or unwillingness to comply with birth control requirements or regional REMS/RevAid programs
Inability to comply with protocol required procedures.
Unwillingness to give written informed consent, unwillingness to participate, or inability to comply with the protocol for the duration of the study
Inability to comply with study and follow-up procedures (i.e. unwilling to undergo protocol-mandated biopsies if feasible)
Inability to comply with the protocol and/or not willing or not available for follow-up assessments
Inability to comply with study and/or follow-up procedures
Inability or unwillingness to receive antithrombotic therapy
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment
Inability to comply with the protocol and/or not willing or not available for follow-up assessments
Unwillingness or inability to receive conventional chemotherapy
Inability to swallow or absorb drug
Unwillingness or inability to comply with the protocol
Inability to comply with the protocol and/or not willing or not available for follow-up assessments.
Unwillingness to participate or inability to comply with the protocol for the duration of the study
Inability to comply with protocol or study procedures
Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol
Cancer of the Liver Italian Program (CLIP) score > 3; inability to comply with study and/or follow-up procedures
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment
Inability to comply with study and follow-up procedures
Inability to comply with protocol requirements
Unwillingness or inability to comply with protocol.
Inability to understand or comply with study protocol
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal condition that could interfere with the oral absorption or tolerance of treatment.
Inability to comply with study and/or follow-up procedures
Inability to comply with study and/or follow-up procedures
Inability to swallow pills
Inability to comply with study and/or follow-up procedures
Unwillingness to participate or inability to comply with the protocol for the duration of the study
Inability to comply with study and/or follow-up procedures
Inability to comply with study and/or follow-up procedures
Inability to comply with study requirements
Inability to comply with the study and/or follow-up procedures.
Inability to comply with study and/or follow-up procedures
Perceived inability to tolerate diagnostic or therapeutic procedures
Inability to provide informed consent or to comply with the schedule of office and treatment visits
Inability to give consent
Inability to comply with study and/or follow-up procedures
Inability to comply with study and follow-up procedures
Inability to comply with protocol required procedures
Is unwilling to give written informed consent, unwillingness to participate, or inability to comply with the protocol for the duration of the study
Inability to comply with study and/or follow-up procedures.
Inability to comply with the protocol activities
Inability to collect adequate stem cells
inability to comply with the protocol activities
Perceived inability to tolerate diagnostic or therapeutic procedures, particularly treatment in radiation isolation
Patient must be able to tolerate the procedures required in this study including periodic blood sampling, study related assessments, and management at the treating institution for the duration of the study. Inability to comply with protocol or study procedures (for example, an inability to swallow tablets) will be an exclusion criterion.
Inability to comply with study and/or follow-up procedures
Inability or unwillingness to comply with the treatment protocol, follow-up, or research tests
Inability or unwillingness to take folic acid, vitamin B12 supplementation or corticosteroids
Inability to comply with study and follow-up procedures
Inability to swallow oral medication or inability or unwillingness to comply with the administration requirements related to alisertib
Unwillingness or inability to comply with study and follow-up procedures
Inability to comply with study or follow-up testing and procedures
Inability to receive TBI.
Subject's inability to comply with study and follow-up procedures, as judged by the Investigator.
No social support or inability to attend study-related visits
Inability to comply with study and/or follow-up procedures
Unwillingness or inability to follow the procedures outlined in the protocol.
Unwillingness or inability to comply with the protocol
Inability to comply with protocol or study procedures
Inability or unwillingness to take folic acid or vitamin B12 or dexamethasone
High risk of inability to comply with therapy in the estimation of the principal investigator (PI)
Unwillingness or inability to comply with the study protocol for any reason.
Inability to comply with study and/or follow-up procedures
Inability to comply with protocol-specified procedures (i.e., treatment, monitoring, or follow-up)
Inability to understand and inability to provide informed consent
Inability or unwillingness to swallow pills
Inability to comply with study and follow-up procedures
Inability to comply with study and follow-up procedures
Inability or unwillingness to swallow pills
Inability to comply with study and follow-up procedures
Unwillingness to participate or inability to comply with the protocol for the duration of the study
Inability to comply with study and follow up procedure
Inability to comply with the study protocol.
Inability to comply with study and/or follow-up procedures
Inability to swallow pills
Inability to comply with requirements of the protocol
Unwillingness or inability to comply with procedures required in this protocol.
Patients with the inability or with foreseeable incapacity, in the opinion of the Investigator, to comply with the protocol requirements.
Inability to consent for the procedure
Likely inability to comply with the protocol or cooperate fully with the investigator and site personnel
Unwillingness or inability to follow the procedures outlined in the protocol
Patients with the inability, in the opinion of the Investigator, to comply with the protocol requirements
Inability to swallow or absorb drug
Inability to home monitor blood pressure
Unwillingness or inability to comply with procedures required in this protocol
Inability to comply with study or follow-up testing and procedures
Inability to comply with study and/or follow up procedures
Inability to comply with protocol and/or not willing or not available for follow-up assessments
Inability to comply with study-related procedures
Known or suspected inability to comply with the study protocol.
Inability to comply with protocol requirements
Known or suspected inability to fully comply with study protocol.
Known or suspected inability to fully comply with study protocol
Unwillingness or inability to follow the procedures required in the protocol.
Inability to consent.
Inability to comply with medical therapy or follow-up
Inability to undergo SRS due to claustrophobia
Inability to comply with the study procedures
Inability of the subject to comply with study procedures and/or follow-up
CAREGIVERS: Inability to complete study questionnaires
Inability or unwillingness to swallow pills
Inability to comply with study and/or follow-up procedures
Unwillingness or inability to comply with mandated blood draws.
Inability to comply with follow up visits
Inability to complete the baseline assessment forms or to understand the recommendations for participation in the study
Inability to exercise
Inability to complete study forms
Cognitive impairment or inability to consent to treatment, as determined by the patient's oncologist
Inability to cooperate with NIPPV
Inability to complete pain self-report
Mental impairment leading to inability to cooperate
Inability or unwillingness to understand or cooperate with study procedures
Mental impairment leading to inability to cooperate
Inability to complete the baseline assessment forms or to understand the recommendations for participation in the study
Inability or unwillingness to follow study protocol.
Inability to comply with the pre-op diet
Inability to swallow pills
Inability to comply with study and/or follow-up procedures
Inability to taste or smell due to medication or health condition
Inability to complete the baseline assessment forms or to understand the recommendations for participation in the study
Inability to comply with protocol requirements including refusal to forego pre-procedural opioid use
Inability to comply with study requirement
Inability to complete all study-related visits
Inability to take medications by mouth
Inability to tolerate imaging procedures in the opinion of the investigator or treating physician
Inability to comply with IL-2 treatment regimen
Inability to complete the baseline assessment forms or to understand the recommendations for participation in the study
Inability or unwillingness to give informed consent
Inability to commit to local follow up for device management
Has inability to give informed consent or comply with study requirements
Inability to comply with follow up regimen
Inability or unwillingness to comply with skin care instructions and follow-up
Inability to comply with study and/or follow-up procedures
Inability to swallow pills
Inability to swallow pills
Known inability to participate in the ongoing appointments for the four months of the study and scheduled follow-up tests.
Inability or unwillingness to cooperate with the study procedures
Mental impairment leading to inability to cooperate
Unwillingness or inability to participate or give informed consent
Inability to swallow pills
Known inability to participate in the scheduled follow-up tests
Inability to understand consent procedures
Known inability to participate in the ongoing appointments for the four months of the study and scheduled follow-up tests
Inability to commit to the intervention schedule
Inability to swallow pills
Inability to comply with protocol and/or not willing or not available for follow-up assessments
Inability or unwillingness of patient, parent, or guardian to consent
Inability to lie in the scanner for 30 minutes
Inability or unwillingness to provide informed consent to the study
Unwillingness or inability to comply with study procedures
Inability to cooperate with the scans
Inability to lie flat for 60-90 minutes
Inability to lie still for the entire imaging time (approximately 30 minutes)
Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
Inability to tolerate imaging procedures in the opinion of the investigator or treating physician
Inability to tolerate imaging procedures, in the opinion of an investigator or treating physician
Inability to give written consent
Inability to adequately oxygenate the patient during the procedure
Inability to lie still for PET scanning
Inability to tolerate imaging procedures, in the opinion of an investigator or treating physician
Inability to tolerate 60 minutes of PET imaging
Inability to comply with study procedures
Inability to tolerate imaging procedures in the opinion of the investigator or treating physician
Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
Inability to lie still for the entire imaging time
Inability to comprehend or unwillingness to follow instructions for the study procedures required per protocol
Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
Inability to tolerate imaging procedures in the opinion of an investigator or treating\r\nphysician
Inability or unwillingness to undergo PET scanning
Inability to comply with protocol requirements
Inability to comply with the photosensitivity precautions associated with the study
Inability to lie still for the duration of the scanning procedure
Inability to tolerate imaging procedures (e.g. claustrophobia, severe pain)
Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
Inability to lie in the scanner for 30 minutes
Inability or unwillingness to cooperate with requirements of this trial
Inability to understand and/or carry out instructions
Inability or unwillingness to undergo the complete series of imaging sessions; inability or unwillingness to complete the one month follow-up
Inability to understand the risks and benefits of the study
Patient Volunteers: Inability to understand the risks and benefits of the study
An inability to lie still for the tests
Unwillingness or inability to give informed consent
Inability to tolerate MRI (e.g., inability to lie flat for > 1 hour)
Inability to lie still for PET scanning
Inability to lie still for PET scanning
Inability to cannulate the common bile duct
Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
Inability to lie still for the entire imaging time
Inability to lie still for PET scanning
Inability to give informed consent or to comply with all study procedures
Inability to lie still for the imaging study
Inability to lie still for the entire imaging time
inability to comply with the protocol
Inability to lie still for the entire imaging time
Inability to tolerate MRI including conditions such as claustrophobia or inability to lay flat for > 45 minutes
Inability to comply with instructions
Physical inability to undergo a scanning procedure (e.g., inability to lie flat for the required period of time – three sessions of roughly an hour each with ten minutes’ rest in between)
Foreseen inability to comply with study requirements
Inability to lie still for imaging
Inability to swallow pills
Inability to undergo leukapheresis
BIODISTRIBUTION COHORT: Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
DYNAMIC COHORT: Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
The patient has an inability or unwillingness to abide by the study protocol or cooperate fully with the investigator or designee.
Inability or unwillingness to swallow pills
Inability to abstain from taking anything by mouth for at least 6 hours
Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol. Note the following pertains to patients enrolled in France
